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Successful treatment outcomes for chronic hepatitis B virus (HBV) infection requires high levels of adherence to treatment. 
We searched three databases and abstracts from two conferences up to January 2018 for studies reporting the proportion of 
patients who were adherent to HBV antiviral therapy and pooled data using random effects meta-analysis. We included 
30 studies, providing data for 23,823 patients. Overall, adherence to treatment was 74.6% (95% confidence interval [CI] 
67.1%-82.1%). Adherence was similar in high-income settings (75.1%; 95% CI, 65.4%-85.0%) and in low-income and 
middle-income settings (72.9%; 95% CI, 57.8%-88.0%). Reported barriers to adherence included forgetting, limited 
understanding of the importance of adherence, and change to routine. Conclusion: There is a need to reinforce assessment 
and reporting of adherence as a routine part of HBV care and to assess the extent to which evidence-based interventions to 
improve adherence to medication for human immunodeficiency virus [HIV] and other chronic diseases are effective for 
HBV infection. (Hepatology Communications 2018;2:1160-1167).
According to World Health Organization estimates, 257 million persons were living with chronic HBV infection worldwide in 
2015, with over two thirds (68%) of infections in the 
African and Western Pacific regions. Together, HBV 
and hepatitis C virus are responsible for 1.2 million 
deaths from cirrhosis and hepatocellular carcinoma 
each year, with two thirds of these deaths attributable 
to HBV.(1)
Antiviral therapy for HBV is effective in suppress-
ing HBV viral load and reducing the risk of developing 
cirrhosis and hepatocellular carcinoma.(2,3) Treatment 
efficacy is dependent on high levels of adherence 
to medication; reduced adherence is the main driver 
of suboptimal treatment response(4) and can lead to 
viral failure, HBV flares, and increased morbidity and 
mortality.(5,6)
Ensuring high levels of adherence to chronic med-
ication is a challenge(7,8); however, the overall pro-
portion of patients adherent to HBV medication 
and associated risk factors have not been assessed. 
We undertook a systematic review and meta-analysis 
to provide an overall estimate of adherence to nucle-
os(t)ide reverse transcriptase inhibitor-based therapy 
for chronic HBV infection and to identify reported 
barriers to adherence.
Abbreviations: CI, confidence interval; HBV, hepatitis B virus; HIV, human immunodeficiency virus.
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Materials and Methods
searCH strategy and 
seleCtion Criteria
This systematic review was conducted according to 
the preferred reporting items for systematic reviews 
and meta-analyses (PRISMA) guidelines(9) and fol-
lowed a study protocol (available from the correspond-
ing author).
Prospective and retrospective observational studies 
that provided quantitative data on adherence to HBV 
therapy for ≥10 patients were included for review. 
Because the aim of this review was to assess adherence 
in program settings, randomized controlled trials were 
excluded as adherence rates are likely to be higher in 
trials compared to routine treatment cohorts due to 
the patient selection prior to trial inclusion and sup-
port provided to study participants. There is no gold 
standard for measuring adherence to medication. We 
included studies that used both subjective measures 
(self-report) and objective measures (pill count, plasma 
drug levels, pharmacy claims, and electronic medical 
records). Viral load was not considered as this can be 
influenced by factors other than patient adherence. If 
studies reported outcomes among patients who had 
previously experienced treatment failure, these patients 
were excluded from analysis; if this was not possible, 
these studies were excluded from the review. Studies 
that used interferon-based regimens were also excluded 
from review due to the high adverse event rate associ-
ated with this drug likely leading to lower adherence. 
Finally, we excluded studies that included patients with 
hepatitis C and hepatitis D coinfection if data could 
not be disaggregated by coinfection status (because 
patients who are coinfected will likely have different 
adherence due to pill burden, disease status, and other 
challenges associated with comorbidities). No language, 
date, or geographic limitations were applied.
Using a sensitive search strategy that combined 
terms for hepatitis B infection, antiviral drugs, and 
adherence, two investigators (N.F., R.S.) screened titles 
and abstracts from MEDLINE through PubMed, 
Embase, and the Cochrane Library to January 31, 
2018. Abstracts from conferences of the European 
Association for the Study of the Liver and American 
Association for the Study of Liver Diseases were 
screened from 2015 to 2017 to identify recent studies 
that may have been completed but not yet published in 
full. Database searches were supplemented by screen-
ing bibliographies of review articles and all included 
full-text articles. The same investigators scanned all 
abstracts and full-text articles and achieved consensus 
on final study inclusions. If multiple studies reported 
outcomes for the same cohort of patients, the study 
with the longest follow-up period was used as the pri-
mary study. If studies reported adherence at multiple 
time points, the longest time point was reported.
Three reviewers working independently (R.S., N.F., 
Z.S.) extracted data using a standardized and piloted 
extraction form that included study characteristics 
(design, year, population, location, HIV coinfection 
status, adherence measure); outcomes, including num-
bers adherent, and reasons for suboptimal adherence; 
and type of HBV therapy. Risk of bias was assessed 
using an adapted prevalence critical appraisal tool.(10)
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statistiCal analysis
Numerators and denominators for the number of 
patients considered optimally adherent within a given 
cohort were extracted according to adherence thresh-
olds as defined by the studies (Supporting Table S1) 
and from these point estimates and corresponding 
95% CIs were calculated and data were pooled follow-
ing transformation using random-effects meta-anal-
ysis.(11,12) Results were stratified by country income 
status according to World Bank classification. The I2 
tests for heterogeneity is not a reliable test for pooled 
proportions,(13) and therefore for this review, hetero-
geneity was assessed using the τ2 statistic (a measure 
of the variance of the effect size parameters across the 
population of studies) and through visual inspection 
of forest plots and subgroup analyses assessing the 
following covariates: income setting, adherence mea-
sure, and duration of follow-up. Meta-regressions were 
carried out to assess the potential influence of income 
setting, duration of follow-up, adherence measure, and 
proportion of male individuals. We analyzed all data 
with Stata version 13.0.
Results
From an initial screen of 878 titles, 30 studies pro-
viding data for 23,823 patients met our eligibility crite-
ria and were taken through for review (Fig. 1).(4-6,14-39) 
The majority (23 studies, 17,057 patients) were from 
high-income settings, mainly the United States (seven 
studies), Australia (four studies), and France (three 
studies). Studies from low-income and middle-income 
settings were carried out in Brazil,(15,29) China,(31,33) 
The Gambia,(40) India,(24) and Zambia.(36) Twelve 
studies were prospective cohorts, 11 were retrospective 
cohorts, and seven were cross-sectional surveys. Most 
studies used self-report (11 studies) as the main adher-
ence measure. All studies were carried out in adults, 
and in all studies the proportion of male patients was 
>50%. Most studies (14) gave patients a single-drug 
therapy, with the rest providing a combination of single 
or dual therapies; entecavir was the most common drug 
used (13 studies). Three studies included patients coin-
fected with HIV. Follow-up ranged from 4 months to 
160 months, with a median follow-up of 16 months. 
Characteristics of included studies are provided in 
Fig. 1. Study selection process. Abbreviations: ART, antiretroviral therapy; IFN, interferon.
878 titles and abstracts screened
51 articles screened
as full text
6 articles included from 
bibliography screen
30 articles included for review
827 excluded as
duplicates, no data, or 
not relevant to study 
question
27 excluded after full text review 
– duplicate (4 ) 
– failure cohort ( 3)
– ART adherence (3)
– IFN-based regimen (4) 
– <10 patients (2)
– unclear denominator ( 9)
– coinfection study and data not 
disaggregated by disease (2)
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Supporting Table S1, and the risk of bias assessment is 
provided in Supporting Table S2.
Overall, adherence to treatment was 74.6% (95% 
CI, 67.1%-82.1%; τ2 = 0.14). Adherence was similar in 
high-income settings (75.1%; 95% CI, 65.4%-85.0%; 
τ2 = 0.20) and in low-income and middle-income set-
tings (72.9%; 95% CI, 57.8%-88.0%; τ2 = 0.21). There 
was substantial heterogeneity (Fig. 2). Adherence strat-
ified by adherence measure was as follows: plasma drug 
levels, 68.5% (95% CI, 59.9%-77.2%); medicine posses-
sion ratio, 69.1% (95% CI, 58.8%-79.4%); self-report, 
69.5% (95% CI, 56.0%-82.9%); electronic medication 
dispenser, 69.8% (95% CI, 60.9%-78.7%); Morisky 
medication adherence scale, 87.0% (95% CI, 82.9%-
91.1%); pharmacy claims, 88.1% (95% CI, 78.8%-
97.3%); pill count, 73.1% (95% CI, 49.6%-96.5%); and 
electronic medical records, 95.4% (95% CI, 91.0%-
99.8%). In subgroup analysis, there was no difference 
in adherence when studies with a follow-up duration 
greater than 12 months (77.4%; 95% CI, 67.7%-87.0%) 
were compared to those with 12 months or less (81.0%; 
95% CI, 63.8%-98.2%), or comparing studies that used 
self-report as an adherence measure (70.2%; 95% CI, 
57.6%-82.9%) versus objective measures (77.1%; 95% 
CI, 67.4%-86.8%), or studies that defined optimal 
adherence as 100% adherence (75.0%; 95% CI, 67.5%-
82.5%) versus <100% adherence (70.6%; 95% CI, 
63.3%-77.9%). These findings were consistent with 
the results of the meta-regression, which was unable 
to identify an association between these covariates and 
adherence outcomes (Supporting Table S3). We also 
used meta-regression to explore a possible association 
Fig. 2. Pooled proportion of patients adherent to HBV medication. Data points represent percentage adherence and 95% CI. Diamonds 
represent pooled proportions. Dotted line indicates the overall pooled proportion.
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between the proportion of male participants (which 
ranged from 55%-100%) and adherence, but again 
found no association.
Barriers to adherence were reported by seven stud-
ies.(5,20,21,24,28,32,39) Among patients with subopti-
mal adherence, the most commonly reported barriers 
to adherence were forgetting (three studies, 81.1%; 
95% CI, 68.7%-93.5%), limited understanding of the 
importance of adherence (two studies, 32.3%; 95% CI, 
17.2%-47.4%), and change to daily routine (two stud-
ies, 27.4%; 95% CI, 4.7%-50.1%). Other challenges, 
reported by single studies included travel (13.3%; 95% 
CI, 3.8%-30.7%), cost of care (70.0%; 95% CI, 45.7%-
88.1%), being busy (12.9%; 95% CI, 3.6%-29.8%), “ran 
out of drugs” (16.1%; 95% CI, 5.4%-33.7%), and no 
perceived improvement in health status (50%; 95% CI, 
27.2%-72.8%).
Discussion
Achieving high levels of adherence is key to suc-
cessful treatment outcomes for chronic HBV infec-
tion. Modeling studies suggesting that, compared to 
optimal adherence of 95%, a lower adherence of 65% 
would lead to 2.6 million additional deaths over a 
15-year period.(41) Our systematic review found mod-
erate adherence to treatment for chronic HBV infec-
tion. Overall, three in four patients were reported to 
be adherent to chronic HBV infection medication, 
and while the optimal level of adherence required to 
achieve therapeutic efficacy is not established and may 
vary by regimen, this is higher than reported for HIV 
infection.(7) In this review, the most common mea-
sure of adherence was self-report, and although we 
found no major difference in adherence by measure, 
other studies have found that self-report overestimates 
adherence,(42) a finding consistent with other disease 
areas.(43) If confirmed, the overall pooled estimate for 
adherence is likely to be lower than reported by this 
review.
This review aimed to estimate the proportion of 
patients who are adherent to chronic HBV infection 
medication. There is no gold standard for measuring 
adherence, and while viral load is considered to be 
the preferred measure, viral load can be influenced 
by factors other than adherence, including drug effi-
cacy, polypharmacy, drug resistance, treatment failure, 
and unknown effects of the disease or drugs. For this 
reason, we did not include studies that reported viral 
load as the only adherence measure, and it would be 
valuable to summarize estimates of viral suppression 
separately to estimates of adherence, as has been done 
for HIV.(7,44,45) We also did not look at biochemical 
response (as defined by normalization of liver ami-
notransferase levels), which is influenced by other 
infectious diseases and chronic liver disease (espe-
cially nonalcoholic fatty liver disease in high-income 
countries).
Entecavir was the most widely used drug reported 
by studies in this review. Entecavir and tenofovir are 
both potent and safe drugs that can be used widely for 
HBV treatment with minimal laboratory monitoring 
and are the preferred options recommended by the 
World Health Organization. Entecavir also appears 
to have a high genetic barrier to resistance, although 
availability is limited in many settings because of its 
comparatively higher cost.
The only previous systematic review, published in 
2012, included only six studies on chronic HBV infec-
tion treatment adherence.(46) That review did not pro-
vide a statistical summary of adherence estimates given 
the limited number of studies identified and concluded 
that nonadherence was infrequent. Our review sug-
gests that suboptimal adherence is an important con-
cern deserving attention. Few studies reported reasons 
for suboptimal adherence, but the limited information 
available is consistent with what is known for adher-
ence to HIV medication, where the most commonly 
reported barriers to adherence include forgetting, 
change to routine, secrecy/stigma, distance to clinic, 
being busy, and stock outs.(45) This suggests that inter-
ventions to improve adherence to medication for HIV 
and other chronic infectious diseases may work for 
chronic HBV infection. Findings from a recent study 
suggest that text messaging could improve adherence 
to chronic HBV infection(47); this is consistent with 
the larger body of evidence supporting text messaging 
to improve adherence to antiretrovirals for HIV.(48) 
Another promising approach to improve retention 
in care is to reduce the frequency of dispensing and 
clinic visits(49); this approach is now widely recom-
mended for HIV treatment and care.(50,51) Other 
proven strategies for improving adherence to HIV 
treatment that could be considered for chronic HBV 
infection include peer support and cognitive behavioral 
therapy.(48)
Strengths of this review include a broad search strat-
egy that allowed for the identification of 24 additional 
articles compared to the previously published review. 
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We chose to exclude studies of patients with a history of 
treatment failure as it can be expected that such patients 
are more likely to be at risk of suboptimal adherence; 
however, routine clinic cohorts can be expected to 
include a proportion of such patients, and this may 
lead to lower overall adherence levels. In the final study 
selection process, only one study was excluded for this 
reason. We anticipated substantial heterogeneity in 
adherence reported from program settings and explored 
potential drivers of heterogeneity in several preplanned 
subgroup analyses. While these analyses were unable 
to identify patient or study characteristics that could 
explain variation in adherence (likely due to the small 
number of studies and inconsistent reporting of covari-
ates), outlier analysis provided some further insights. 
Studies reporting lower average adherence included a 
study of noninjecting drug users in Brazil(29) and the 
use of older drugs associated with a greater frequency 
of adverse events. Other covariates that could explain 
potential differences in adherence, including age, disease 
progression and duration, and concomitant medication, 
were too infrequently reported to be able to assess. The 
main concerns with respect to risk of bias include retro-
spective study designs and the use of subjective adher-
ence measures as well as different thresholds for defining 
optimal adherence, which ranged from >70% to 100% 
adherence (Supporting Table S1). The main limitation 
of this systematic review is the limited evidence base, in 
particular the limited reporting from low-income and 
middle-income settings; this partly reflects the fact that 
access to HBV therapy has until recently been limited in 
resource-limited settings, in particular Africa. As access 
to affordable treatment for HBV therapy is increasing 
globally, objective measures of adherence should be inte-
grated into routine care. Publication bias is a concern 
for any systematic review and in particular for reviews 
of routine program performance (as only a minority of 
outcomes from routine programs are published). We 
cannot know how publication bias may affect the find-
ings presented in this review as studies reported a range 
of adherence levels, indicating that publications are not 
limited to positive adherence results.
This review also found only limited information 
regarding patient-reported barriers to adherence, and 
there is a need for a better understanding of causes of 
nonadherence. More fundamentally, there is a need 
to improve awareness of the disease; in many low-in-
come settings, knowledge of HBV in the general pop-
ulation is very limited, with less than 1% of people in 
The Gambia reporting to have heard of hepatitis B, 
although most are familiar with HIV and malaria.(52) 
Future research should focus both on identification 
of potential risk factors (including age, sex, coinfec-
tion status, and stage of disease) and patient-reported 
barriers to help identify patients at higher risk of non-
adherence and supportive interventions. Consistent 
reporting of adherence measures would also help com-
parability of adherence estimates.
In conclusion, our review provides evidence of mod-
erate levels of adherence to chronic hepatitis B medi-
cation but highlights that more attention is needed to 
further improve adherence. Further research is encour-
aged, particularly from low-income and middle-income 
settings, to better understand the causes of suboptimal 
adherence and to assess the impact of adherence-sup-
port interventions. Lessons can be learned from other 
chronic infectious disease areas, notably HIV.
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